Late state pre-clinical development of new cCML drug

[Guest guest]

Hi, I was prowling the internet and found that Deciphera was ready to begin in

the first quarter of 2009 as a new clinical trial for CML. Not much information

is available as they are yet to start. I believe that MDACC will be one of the

trial centers. I think it is exciting to have another drug about to make it's

debut, which means another choice for us. Here is the introduction to DCC-2036.

BCR-ABL Program Chronic Myelogeous Leukemia (CML) program

DCC-2036 inhibits BCR-ABL kinase, an oncogenic fusion protein kinase resulting

from chromosomal translocation (Philadelphia + chromosome). BCR-ABL is causative

of myeloproliferative diseases, including chronic myelogenous leukemia (CML).

http://www.deciphera.com/BCR-ABL.html.

_____________________________________________

Singapore, Oct 6, 2008: Eli Lilly, a leading innovation-driven corporation and

privately-held Deciphera Pharmaceuticals, have entered into a collaboration and

worldwide licensing agreement related to latter's preclinical B-Raf kinase

inhibitor program for the study of potential oncology therapeutics. The

collaboration will advance their B-Raf kinase 'switch pocket' inhibitors into

the clinic and ultimately to patients in need of these therapies.

http://www.biospectrumasia.com/Content/061008OTH7294.asp

Deciphera is pursuing two distinct strategies centered on B-RAF inhibition. The

first strategy seeks potent and highly selective BRAF inhibitors. The second

strategy pursues B-RAF inhibitors which also inhibit other kinases of interest.

http://www.deciphera.com/inthenews.html

______________________________________________

Singapore, Nov 5, 2008: Melbourne based Mesoblast has commenced a phase I/II

clinical trial in the US using the patented allogeneic, or " off-the-shelf " ,

Mesenchymal Precursor Cells (MPCs) in up to 30 patients with haematologic

malignancies undergoing bone marrow transplantation.

This follows clearance by the United States Food and Drug Administration (FDA)

of an Investigational New Drug (IND) submission, and ethics approval by the

Institutional Review Board (IRB) at the University of Texas M. D.

Cancer Center in Houston. The trial will be funded through a grant awarded by

the United States National Institutes of Health (NIH).

http://www.biospectrumasia.com/content/051108AUS7572.asp

This is a lot to read, but since this is a weekend, you can take your time.

FYI,

Lottie